PIK3CA and melanoma: In melanoma, resistance mechanisms emerging after treatment with BRAF-targeted therapy are well known and they correspond mainly to recovery of MEK/ERK signaling or activation of PI3K/AKT signaling, through BRAF amplification and alternative splicing or alterations in RAS, MEK, and ERK10.